- Home
- MNSO vs IONS Comparison
MNSO vs IONS Comparison
Compare MNSO & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSO
- IONS
- Stock Information
- Founded
- MNSO 2013
- IONS 1989
- Country
- MNSO China
- IONS United States
- Employees
- MNSO N/A
- IONS N/A
- Industry
- MNSO Department/Specialty Retail Stores
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- MNSO Consumer Discretionary
- IONS Health Care
- Exchange
- MNSO Nasdaq
- IONS Nasdaq
- Market Cap
- MNSO 6.8B
- IONS 6.8B
- IPO Year
- MNSO 2020
- IONS 1991
- Fundamental
- Price
- MNSO $21.78
- IONS $70.38
- Analyst Decision
- MNSO Strong Buy
- IONS Strong Buy
- Analyst Count
- MNSO 2
- IONS 21
- Target Price
- MNSO $24.10
- IONS $80.71
- AVG Volume (30 Days)
- MNSO 694.0K
- IONS 2.1M
- Earning Date
- MNSO 11-21-2025
- IONS 10-29-2025
- Dividend Yield
- MNSO 3.00%
- IONS N/A
- EPS Growth
- MNSO N/A
- IONS N/A
- EPS
- MNSO 1.06
- IONS N/A
- Revenue
- MNSO $2,600,350,931.00
- IONS $966,957,000.00
- Revenue This Year
- MNSO $27.70
- IONS $27.96
- Revenue Next Year
- MNSO $19.11
- IONS $2.33
- P/E Ratio
- MNSO $19.58
- IONS N/A
- Revenue Growth
- MNSO 21.03
- IONS 20.41
- 52 Week Low
- MNSO $13.95
- IONS $23.95
- 52 Week High
- MNSO $27.71
- IONS $76.78
- Technical
- Relative Strength Index (RSI)
- MNSO 50.06
- IONS 47.14
- Support Level
- MNSO $20.35
- IONS $71.48
- Resistance Level
- MNSO $21.60
- IONS $76.78
- Average True Range (ATR)
- MNSO 0.44
- IONS 2.48
- MACD
- MNSO -0.02
- IONS -0.65
- Stochastic Oscillator
- MNSO 57.56
- IONS 32.36
About MNSO MINISO Group Holding Limited
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand, which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from the MINISO brand segment. Geographically, it derives a majority of its revenue from China.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.